Ravuconazole

N/A

Report date: 2022/05/17 17:51:16
NME

Base Information

Drug NameRavuconazole
Drug Alias NameRavuconazol雷夫康唑Ravuconazolum拉夫康唑BMS-207147 +[6] 
ClassificationSmall molecules > Heterocyclic drugs > Antifungals
Mechanisms of ActionLanosterol 14α-demethylase inhibitors
TargetsLanosterol 14α-demethylase
Therapy Area/IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative Diseases +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)Bristol-Myers Squibb CompanyEisai Co Ltd
Active IndicationsN/A
Inactive IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative Diseases +[14] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG